The Latin America, Middle East and Africa Large Molecule Drug Substance CDMO Market would witness market growth of 11.0% CAGR during the forecast period (2022-2028).
The development of CDMOs is being driven by their assistance in meeting deadlines and overcoming difficulties, like the fragility of the large molecule-based active compounds, in the early drug development stages. Numerous innovative techniques have been developed that combat the fragility and complexity issues of large molecules.
For example, techniques like encapsulation and buffer use work by promoting the stabilization of large molecules, thereby protecting them. The rising elderly population, worldwide growth of economy, and new product launches are propelling the growth of the pharmaceutical industry and CDMOs exponentially.
Similarly, the increasing preference for gene and cell therapies are advancing the growth of the biologics. This growth further perpetuates its positive effect on the originator biologics as well. One of the major drivers that are influencing the growth of biologics is the rising cancer therapies demand. As a result, there has been a steady increase in the number of large molecules being approved.
In this region, the healthcare industry has significantly grown and has become one of the GCC's most important sectors for promoting economic diversification. Consequently, public-private partnerships are being encouraged, and private businesses are compelled to build infrastructure for further developing the drug manufacturing processes. In addition, the increasing preference for preventive care over curative care by the younger, healthier population is pushing the sector positively.
The Brazil market dominated the LAMEA Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $295 million by 2028. The Argentina market is experiencing a CAGR of 11.6% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10.7% during (2022 - 2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Large Molecule Drug Substance CDMO Market is Predict to reach $19.2 Billion by 2028, at a CAGR of 8.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
By Application
By Service
By End-user
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 